

Global Hemophilia Community Survey Reveals Unspoken Compromises

Pfizer commissioned a global survey with The Harris Poll to better understand the experiences of more than 1,000 people living with hemophilia, and their caregivers.


The findings highlight the complexities of hemophilia care today.

- While many patients report some level of satisfaction with their current treatment, they continue to experience both physical and emotional burdens, underscoring persistent patient needs.
- Interest in newer treatment options is high, though familiarity and understanding are still evolving.
- Access to trusted information through healthcare providers, patient support groups and community networks is vital to support shared decision making in hemophilia care.


Key Takeaways From Patients and Caregivers

1. Treatment satisfaction doesn't always reflect optimal care, leaving many patients with unspoken compromises
2. Treatment decisions are shaped by both clinical benefits and how medicine fits into daily life
3. Healthcare providers and patient advocacy groups are trusted partners in navigating treatment choices

The Emotional and Physical Burdens of Hemophilia Persist



A Closer Look at Patients' Treatment Satisfaction Reveals Room for Improvement




Clinical Efficacy and Shared Decision Making Drive Confidence in Treatments

Patients' key priorities when considering a change in treatment include:



Patient Advocacy Groups and Healthcare Providers Remain Trusted Guides



Who we spoke to

In partnership with The Harris Poll

About the survey: Pfizer's survey consisted of 1,008 participants (502 hemophilia patients and 506 caregivers) across four countries (United States, Brazil, Japan, and Germany).

The 17-minute online survey was fielded from February through March, 2026, and conducted using online panels.

The questionnaire was informed by interviews with hemophilia community leaders.

